Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Highlights Semaglutide medications like Ozempic may cause facial changes. You can take steps to help minimize or prevent ...

Many people experience a serious return of appetite, cravings and weight after coming off Ozempic, and having read far too ...

TeleRare Health® announced it is offering Virtual Genomic Consults across Minnesota, for adult and pediatric patients facing difficulties navigating the diagnosis of their rare or genetics-based ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...